GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
pharmaphorum1d
ERS: GSK reveals data behind new asthma hope depemokimab
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
Daily13m
EMA establishes regular procedure for scientific advice on certain high-risk medical devices
European Medicines Agency (EMA), in close collaboration with the European Commission, has established a standard procedure ...
EconoTimes5d
GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
pharmaphorum5d
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
FiercePharma5d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...